Biogen, headquartered in Cambridge, Massachusetts, specializes in therapies for neurological diseases, employing 7,570 people and offering treatments for conditions like MS, SMA, Alzheimer's, and ALS. Their product portfolio includes TECFIDERA, SPINRAZA, and collaborations on LEQEMBI and others.
BIIB has been in the news recently: Biogen Inc. has announced plans to invest an additional $2 billion in its manufacturing facilities located in North Carolina's Research Triangle Park. This investment is part of the company's ongoing efforts to expand its operations in the region.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
